Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 5/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16185144 | 0.93 | CHRNA7 (0.44) | GRM5CHRNA7KITEGFRERBB2 | |
| SCHEMBL16185140 | 0.91 | GRM5 (0.48) | GRM5CHRNA7KITEGFRLMNA | |
| SCHEMBL14474194 | 0.88 | KIT (0.39) | KITLMNAMAP3K11CYP1A2CYP3A4 | |
| SCHEMBL16184852 | 0.88 | HSD17B10 (0.47) | GRM5MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16185150 | 0.87 | GRM5 (0.40) | GRM5CHRNA7KITEGFRERBB2 | |
| SCHEMBL16185160 | 0.87 | GRM5 (0.40) | GRM5CHRNA7KITEGFRERBB2 | |
| SCHEMBL16185128 | 0.85 | GRM5 (0.41) | GRM5CHRNA7EGFRLMNACYP1A2 | |
| SCHEMBL16185167 | 0.84 | GRM5 (0.38) | GRM5CHRNA7KITEGFRERBB2 | |
| SCHEMBL16185168 | 0.84 | CHRNA7 (0.37) | GRM5CHRNA7KITLMNAMAPT | |
| SCHEMBL16185169 | 0.84 | S1PR1 (0.43) | GRM5CHRNA7KITEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GRM5 37/4885CHRNA7 349/4885KIT 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.